Abstract:Neoadjuvant concurrent chemoradiation has become the standard treatment in locally advanced rectal cancer. The target therapy combined with chemoradiation also showed encouraging results. However, there are about 20-30% patients who couldn't get benefit from tumor downstaging due to radio resistance. COX-2 may be involved in tumor radio resistance mechanism. The application of selective COX-2 inhibitor Celecoxib in combination with chemoradiation is appealing in the aspects of overcoming the radio resistance and acting as a potential target therapy. This study is to investigate the COX-2 expression and its significance in locally advanced rectal cancer treated with neoadjuvant concurrent radiation with Capacitabine/Oxaliplatin and Celecoxib. Forty patients with locally advanced rectal cancer were treated in Cancer Hospital, Fudan University from June 2006 to Dec. 2007. All patients were staged IIIB-C based on MRI and endorectal ultrasound examination. All patients underwent pelvic irradiation of 45Gy/25fx/35day. The regimen of concurrent chemotherapy is: Capacitabine 625mg/m2, bid (Mon-Fri.); Oxaliplatin 50mg/m2, weekly and Celecoxib 200mg bid during the whole course. The patients were operated 5-8 weeks followed by concurrent chemoradiation and Celecoxib. Tumor regression grading was evaluated according to the criteria by Rödel. 34 pretreatment biopsies and 24 surgical specimens of COX-2 expression were examined using immunohistochemistry method. Of all specimens, there were 19 patients who had both pretreatment and surgical specimens. Pathological complete response (pCR) was observed in 4 of 40 patients (10%). Downstaging with respect to the tumor stage was observed in 40% patients. The tumor regression grades post neoadjuvant treatment was recorded as: grade 0-1 in 37.5%, grade 2-3 in 50%, grade 4 in 12.5%. COX-2 expression increased in 14 of 19 patients (73.7%) with both pre and post tests from a median of 0% before to 40% after chemoradiation (p = 0.003). COX-2 expression in pretreatment biopsies was not significantly correlated with tumor regression (p = 0.737) and tumor downstaging (p = 0.134). This study showed COX-2 expression in pretreatment biopsies is not associated with tumor regression or tumor downstaging. Elevated expressions of COX-2 post treatment were observed in the majority of tested patients with small samples. More patients with prolonging duration or escalating the dose of celecoxib may need further investigated.

Celecoxib Enhances Radiosensitivity Via Induction of G2-M Phase Arrest and Apoptosis in Nasopharyngeal Carcinoma

Celecoxib Enhances the Sensitivity of Non-Small-cell Lung Cancer Cells to Radiation-Induced Apoptosis Through Downregulation of the Akt/mTOR Signaling Pathway and COX-2 Expression

Celecoxib's Radiosensitizing Effects on Three Different Human Cancer Cell Lines

Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell.

Radiosensitizing Effects of COX-2 Inhibitor Celecoxib on the Five Different Human Malignent Cell Lines

Radiosensitivity Enhancement by Combined Treatment of Nimotuzumab and Celecoxib on Nasopharyngeal Carcinoma Cells

Celecoxib and Afatinib Synergistic Enhance Radiotherapy Sensitivity on Human Non-Small Cell Lung Cancer A549 Cells

Enhancement of Radiation Sensitivity by Erlotinib and Celecoxib in A549 Human Lung Cancer Cell Line

Study of the mechanism of radiation sensitizing effect of celecoxib on breast cancer cells with different estrogen receptors status

Inhibition of Cyclooxygenase‑2 Sensitizes Lung Cancer Cells to Radiation‑induced Apoptosis

Celecoxib Enhances Anticancer Effect of Cisplatin and Induces Anoikis in Osteosarcoma Via PI3K/Akt Pathway.

Radiosensitizing effects of cyclooxygenase-2 selective inhibitor LM-1685 on A549 human lung adenocarcinoma cells

Radiosensitizing Effect of Celecoxib on Human Pancreatic Carcinoma

Celecoxib Enhances the Radiosensitivity of HCT116 Cells in a COX-2 Independent Manner by Up-Regulating BCCIP.

Celecoxib Alleviates Radiation-Induced Brain Injury in Rats by Maintaining the Integrity of Blood-Brain Barrier

Radiosensitization of Celecoxib on Human Lung Adenocarcinoma Cell Line A549 and Inhibition of Migration Ability in Vitro

Effects of autophagic cell death in the role of celecoxib' radiosensitizing on human glioma SHG-44 cell line

Celecoxib Radiosensitizes the Human Cervical Cancer HeLa Cell Line Via a Mechanism Dependent on Reduced Cyclo-Oxygenase-2 and Vascular Endothelial Growth Factor C Expression

Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent manner.

Effect of Celecoxib in Combination with X-ray on the Apoptosis of Human Cholangiocarcinoma Cell Line QBC939 in Vitro

The Role of Cox-2 Expression in Locally Advanced Rectal Cancer Treated with Neoadjuvant Concurrent Radiation with Capecitabine/Oxaliplatin and Celecoxib